[go: up one dir, main page]

MX2021007001A - Moleculas inhibidoras de acido nucleico de cadena doble que contienen un tribucle. - Google Patents

Moleculas inhibidoras de acido nucleico de cadena doble que contienen un tribucle.

Info

Publication number
MX2021007001A
MX2021007001A MX2021007001A MX2021007001A MX2021007001A MX 2021007001 A MX2021007001 A MX 2021007001A MX 2021007001 A MX2021007001 A MX 2021007001A MX 2021007001 A MX2021007001 A MX 2021007001A MX 2021007001 A MX2021007001 A MX 2021007001A
Authority
MX
Mexico
Prior art keywords
double
nucleic acid
acid inhibitor
tribucle
inhibitor molecules
Prior art date
Application number
MX2021007001A
Other languages
English (en)
Inventor
Bob Dale Brown
Original Assignee
Dicerna Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dicerna Pharmaceuticals Inc filed Critical Dicerna Pharmaceuticals Inc
Publication of MX2021007001A publication Critical patent/MX2021007001A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3515—Lipophilic moiety, e.g. cholesterol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

En el presente documento se proporcionan moléculas inhibidoras de ácido nucleico de cadena doble que tienen una hebra de sentido con una estructura de tallo-bucle y una hebra de antisentido, donde la porción de bucle de la estructura de tallo-bucle es un tribucle; también se proporcionan métodos y composiciones para reducir la expresión de genes diana y métodos y composiciones para tratar una enfermedad de interés.
MX2021007001A 2018-12-12 2019-11-13 Moleculas inhibidoras de acido nucleico de cadena doble que contienen un tribucle. MX2021007001A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862778759P 2018-12-12 2018-12-12
PCT/US2019/061241 WO2020123083A1 (en) 2018-12-12 2019-11-13 Double-stranded nucleic acid inhibitor molecules containing a triloop

Publications (1)

Publication Number Publication Date
MX2021007001A true MX2021007001A (es) 2021-10-13

Family

ID=71076672

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021007001A MX2021007001A (es) 2018-12-12 2019-11-13 Moleculas inhibidoras de acido nucleico de cadena doble que contienen un tribucle.

Country Status (13)

Country Link
US (1) US20220064640A1 (es)
EP (1) EP3894560A4 (es)
JP (2) JP7535047B2 (es)
KR (1) KR20210127917A (es)
CN (1) CN113454221A (es)
AU (1) AU2019397247A1 (es)
BR (1) BR112021011294A2 (es)
CA (1) CA3122930A1 (es)
CL (1) CL2021001552A1 (es)
IL (1) IL283775A (es)
MX (1) MX2021007001A (es)
SG (1) SG11202106046XA (es)
WO (1) WO2020123083A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020123083A1 (en) * 2018-12-12 2020-06-18 Dicerna Pharmaceuticals, Inc. Double-stranded nucleic acid inhibitor molecules containing a triloop
WO2020226960A1 (en) 2019-05-03 2020-11-12 Dicerna Pharmaceuticals, Inc. Double-stranded nucleic acid inhibitor molecules with shortened sense strands
JP2023538284A (ja) * 2020-08-04 2023-09-07 ダイセルナ ファーマシューティカルズ， インコーポレイテッド Ｐｌｐ１発現を阻害するための組成物及び方法
JP2024528697A (ja) 2021-07-20 2024-07-30 エイジーエス・セラピューティクス・ソシエテ・パール・アクシオン・サンプリフィエ 微細藻類由来の細胞外小胞、その調製および使用
WO2023144127A1 (en) 2022-01-31 2023-08-03 Ags Therapeutics Sas Extracellular vesicles from microalgae, their biodistribution upon administration, and uses
KR20250005108A (ko) * 2022-04-15 2025-01-09 다이서나 파마수이티컬, 인크. Scap 활성을 조절하기 위한 조성물 및 방법
WO2023232976A1 (en) 2022-06-03 2023-12-07 Ags Therapeutics Sas Extracellular vesicles from genetically-modified microalgae containing endogenously-loaded cargo, their preparation, and uses
EP4608424A1 (en) 2022-10-24 2025-09-03 AGS Therapeutics SAS Extracellular vesicles from microalgae, their biodistribution upon intranasal administration, and uses thereof
WO2025176847A1 (en) 2024-02-21 2025-08-28 Ags Therapeutics Sas Ocular delivery of active agents via microalgae extracellular vesicles

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006125977A2 (en) * 2005-05-25 2006-11-30 The University Of York Hybrid interfering rna
AU2009293636A1 (en) * 2008-09-22 2010-03-25 Dicerna Pharmaceuticals, Inc. Compositions and methods for the specific inhibition of gene expression by dsRNA possessing modifications
WO2010047216A1 (ja) * 2008-10-23 2010-04-29 国立大学法人 東京大学 microRNAの機能阻害法
EP2562257A4 (en) * 2010-04-19 2014-10-01 Riken PROCESS FOR STABILIZING FUNCTIONAL NUCLEIC ACIDS
EP2781598B1 (en) * 2011-11-16 2018-08-08 Osaka City University Nucleic acid molecule for inhibiting activity of rnai molecule
DK3569711T3 (da) * 2014-12-15 2021-02-22 Dicerna Pharmaceuticals Inc Ligandmodificerede dobbeltstrengede nukleinsyrer
EP3429598A4 (en) * 2016-03-16 2020-04-01 Dicerna Pharmaceuticals, Inc. COMPOSITIONS AND METHODS FOR TREATING DISEASES AND DISORDERS ASSOCIATED WITH BETA-CATENIN
AU2017321892A1 (en) * 2016-09-02 2019-02-28 Dicerna Pharmaceuticals, Inc. 4'-phosphate analogs and oligonucleotides comprising the same
WO2019006375A1 (en) * 2017-06-29 2019-01-03 Dicerna Pharmaceuticals, Inc. COMPOSITIONS AND METHODS FOR INHIBITING HMGB1 EXPRESSION
CA3094008A1 (en) * 2018-04-13 2019-10-17 Dicerna Pharmaceuticals, Inc. Double-stranded nucleic acid inhibitor molecules modified with tm-increasing nucleotides
WO2020123083A1 (en) 2018-12-12 2020-06-18 Dicerna Pharmaceuticals, Inc. Double-stranded nucleic acid inhibitor molecules containing a triloop

Also Published As

Publication number Publication date
JP2024109582A (ja) 2024-08-14
SG11202106046XA (en) 2021-07-29
CA3122930A1 (en) 2020-06-18
JP2022521877A (ja) 2022-04-13
US20220064640A1 (en) 2022-03-03
AU2019397247A1 (en) 2021-06-24
EP3894560A1 (en) 2021-10-20
JP7748500B2 (ja) 2025-10-02
KR20210127917A (ko) 2021-10-25
CL2021001552A1 (es) 2021-11-26
JP7535047B2 (ja) 2024-08-15
IL283775A (en) 2021-07-29
BR112021011294A2 (pt) 2021-08-31
EP3894560A4 (en) 2022-10-19
CN113454221A (zh) 2021-09-28
WO2020123083A1 (en) 2020-06-18

Similar Documents

Publication Publication Date Title
MX2021007001A (es) Moleculas inhibidoras de acido nucleico de cadena doble que contienen un tribucle.
CO2020001354A2 (es) Métodos y composiciones para tratar un evento de sangrado en un sujeto que padece hemofilia un arni, por ejemplo, un ácido ribonucleico de hebra doble (arnhd), composiciones dirigidas al gen serpinc1 y métodos para usar dicho arni, por ejemplo, arnhd, composiciones para tratar un evento de sangrado en un sujeto que tiene una hemofilia (por ejemplo, con o sin inhibidores).
MX2020012048A (es) Composiciones de acido ribonucleico de interferencia (arni) contra el angiotensinogeno (agt) y metodos para su uso.
MX2025007610A (es) Composiciones de arni de 17beta-hidroxiesteroide deshidrogenasa tipo 13 (hsd17b13) y metodos de uso de las mismas
MX2020010802A (es) Moleculas inhibidoras de acidos nucleicos de caracter bicatenario modificadas con nucleotidos que aumentan la tm.
EA201790420A1 (ru) Средства, представляющие собой модифицированную двухнитевую рнк
JO3558B1 (ar) تركيبات وطرق لتثبيط التعبير الجيني عن hao1 (حمض أوكسيداز هيدروكسيلي 1 (أوكسيداز جليكولات))
EA202191630A1 (ru) ХИМИЧЕСКИ МОДИФИЦИРОВАННЫЕ КОНСТРУКЦИИ ДЛЯ RNAi И ПУТИ ИХ ПРИМЕНЕНИЯ
MX2022012561A (es) Composiciones y metodos para silenciar la expresion de la subunidad alfa tipo ix dependiente del voltaje del canal de sodio (scn9a).
CY1122975T1 (el) Συνθεσεις και μεθοδοι για την αναστολη της εκφρασης του γονιδιου alas1
CR20190294A (es) COMPOSICIONES DE ARNi DE SERPINA1 Y SUS MÉTODOS DE USO
EA202191629A1 (ru) Конструкции для rnai, предназначенные для подавления экспрессии pnpla3
MX2024009873A (es) Construcciones de arni para inhibir expresion de asgr1 y metodos para su uso.
PE20241933A1 (es) Composiciones y metodos para inhibir la expresion de la proteina angiotensinogeno (agt)
AR120341A1 (es) COMPOSICIONES DE AGENTES DE ARNi CONTRA LA HUNTINGTINA (HTT) Y SUS MÉTODOS DE USO
CL2021001488A1 (es) Transposasa de piggybac mutada
BR112021006520A2 (pt) ácido ribonucleico de fita dupla que inibe a expressão de c5 complementar
MX385871B (es) Composiciones y metodos para inhibir la expresion del gen lect2.
CL2021002842A1 (es) Moléculas inhibidoras de ácido nucleico bicatenario con cadenas de sentido acortadas
CR20160594A (es) Sistema de expresión génica
MX2025010451A (es) Composiciones y métodos para la inhibición de la expresión de genes de la subunidad beta e de la inhibina (inhbe)
UY37936A (es) AGENTES iARN Y COMPOSICIONES PARA INHIBIR LA EXPRESIÓN DEL RECEPTOR DE ASIALOGLICOPROTEÍNA 1
AR083445A1 (es) siARN CONTRA LA FIBROSIS
MX2022012493A (es) Composiciones y metodos para el silenciamiento de la expresion de miocilina (myoc).
WO2021202443A3 (en) Compositions and methods for silencing dnajc15 gene expression